Clinical Overview

Seborrheic keratosis is the most common benign skin growth in adults, occurring predominantly in middle-aged and elderly populations. These growths are characterized by waxy, scaly surface and appearance of being "stuck on" the skin. While clinically benign and non-premalignant, seborrheic keratoses can be cosmetically concerning, subject to irritation from clothing friction, or occasionally misdiagnosed as melanoma, necessitating either removal or reassurance. The condition increases with age and accumulates over time, with most individuals having multiple lesions.

Epidemiology

Seborrheic keratosis affects 83% of adults over age 50, with prevalence increasing with age (mean age at presentation 50-60 years). Both men and women are equally affected. Prevalence is higher in Caucasian populations (83%) compared to African American (60%) and Hispanic (70%) populations. Geographic variation exists with higher incidence in sun-exposed regions, though seborrheic keratoses are not sun-induced (occur in covered areas equally). Average person develops 10-40 seborrheic keratoses by age 80. Genetics play significant role with familial clustering and autosomal dominant inheritance patterns described in 30-50% of cases.

Pathophysiology

Seborrheic keratosis arises from benign proliferation of basal keratinocytes with histologic variants including acanthotic, hyperkeratotic, and adenoid types. The characteristic "stuck on" appearance reflects proliferation of surface keratinocytes creating lifted appearance. Comedone-like keratin-filled openings ("pseudocysts") appear as dark plugs due to surface keratin accumulation and melanin from trapped melanocytes. Immunohistochemistry reveals high expression of p16 and cyclin D1, consistent with clonal proliferation. Somatic mutations in FGFR3 gene have been identified in 30-40% of seborrheic keratoses, conferring growth advantage. Unlike melanoma, seborrheic keratoses lack dermal invasion, cytologic atypia, and junctional component extending into deeper dermis. The lesions derive from maturation of basal cells following FGFR3 activation.

Clinical Presentation

Seborrheic keratoses typically present as solitary lesions or multiple grouped lesions on trunk, head, and neck. Individual lesions range from 0.5-3 cm diameter, though larger lesions (5-10 cm) occur. Surface is characteristically waxy, scaly, or warty with variable color (light tan to dark brown to black). Lesions appear sharply demarcated from surrounding skin and seem to rest on rather than invade skin surface. Keratotic crusts may be present. Common sites: back, chest, scalp, face (less common), and extremities. Many lesions are asymptomatic but become symptomatic if repeatedly traumatized by clothing causing itching, bleeding, or secondary irritation. Color variation (tan, brown, black) rarely indicates malignant transformation as that does not occur in seborrheic keratosis.

Diagnosis

Clinical diagnosis is usually straightforward based on morphology: waxy, scaly surface with "stuck on" appearance, dark plugs (keratotic debris), and sharp demarcation. Dermoscopy is helpful, showing milia-like cysts (pseudocysts filled with keratin) and comedo-like openings (dark keratotic plugs), both pathognomonic features. Most concerning feature in seborrheic keratosis is misdiagnosis as melanoma due to dark color in some lesions. Key discriminators: seborrheic keratosis lacks asymmetry, irregular borders, color variation typical of melanoma; surface is granular and waxy rather than glossy. Biopsy is not routinely needed but is appropriate if melanoma cannot be excluded clinically or dermoscopically. Histology confirms diagnosis: proliferation of benign basaloid keratinocytes with no dermal invasion, atypia, or mitotic activity. Absence of junctional component extending into dermis confirms benignity.

Treatment Algorithm

Observation: Most seborrheic keratoses require no treatment as they are benign and carry zero malignant potential. Reassurance is appropriate for asymptomatic lesions. However, patients often desire removal for cosmetic reasons or due to irritation from frequent trauma.

Cryotherapy: Liquid nitrogen application for 10-15 seconds per lesion is most common office procedure. Single freeze-thaw cycle achieves 80-85% clearance in one treatment, with residual lesions responding to repeat treatment in 4-6 weeks. Advantages: rapid, minimal pain, no anesthesia required. Disadvantages: hypopigmentation (10-15% in darker skin types), occasional incomplete response requiring repeat treatment (15-20%), postinflammatory hyperpigmentation (5-10%), and blister formation (15-20%) lasting 1-2 weeks. Cryotherapy generally preferred for small to medium lesions (<2 cm).

Shave Excision/Curettage: Lesion is anesthetized with 1% lidocaine and scraped off with curette or surgical blade. Hemostasis achieved with electrocautery or topical hemostatic agents. Achieves >95% removal of lesional tissue in single treatment. Risk of hypertrophic scarring (<5%), postinflammatory hyperpigmentation (5-10%), and incomplete removal if lesion extends deeply (<5%). Cosmetic outcome excellent with minimal scarring. Preferred technique for larger lesions (2-5 cm) or those with significant keratin plaques.

Electrocautery: Local anesthesia with 1% lidocaine, then electrical cauterization destroys lesional tissue. Single treatment removes 85-90% of lesions. Risk of hypertrophic scar (5-10%), particularly on chest/back. Advantages: hemostasis achieved simultaneously with tissue destruction. Disadvantages: potential for deeper thermal injury causing scarring.

Laser Therapy: CO2 laser vaporization removes seborrheic keratosis with excellent cosmetic outcome and minimal scarring (<1% hypertrophic scar risk). Single treatment achieves 95%+ clearance. Advantages: precise control, excellent hemostasis, minimal collateral damage. Disadvantages: cost, potential for postinflammatory hyperpigmentation (10-15%), requires trained operator. Preferred for facial lesions where cosmesis is paramount.

Combination Therapy: For very large lesions or thick seborrheic keratoses, combination of curettage/shave excision followed by electrocautery or laser provides optimal removal and hemostasis. Initial mechanical removal followed by cauterization of base prevents recurrence.

Prognosis

Seborrheic keratosis is entirely benign with zero risk of malignant transformation. Recurrence is uncommon (<5%) after adequate removal with curettage, electrocautery, or laser. Cryotherapy alone has slightly higher recurrence (10-15%) requiring repeat treatment. New seborrheic keratoses will continue to develop with advancing age. Cosmetic outcomes are excellent with most treatments, particularly cryotherapy and laser. Permanent scarring is rare (<5%) with properly performed techniques. Hypopigmentation (cryotherapy) may persist permanently (50% of cases) but typically improves over 6-12 months. Postinflammatory hyperpigmentation usually resolves within 3-6 months with strict photoprotection.

When to See a Dermatologist

Consult dermatology if any of the following apply: diagnostic uncertainty (lesion mimics melanoma), frequent irritation or bleeding from trauma, cosmetic concern, or multiple lesions requiring efficient removal. Dermatologists can perform diagnostic dermoscopy and biopsy if needed, and select optimal removal technique based on size, location, and skin type.

Frequently Asked Questions

Q: Can seborrheic keratosis turn into skin cancer?
A: No, seborrheic keratosis does not transform into skin cancer. It is a benign growth with zero cancer potential. However, their dark appearance can occasionally resemble melanoma, which is why dermatologists sometimes biopsy them to confirm they are seborrheic keratosis and not melanoma. Once confirmed, there is no need for concern.

Q: Why do I have so many seborrheic keratoses?
A: Seborrheic keratosis is the most common benign skin growth and increases steadily with age. Most people develop multiple lesions over their lifetime, particularly after age 50. If your family members have seborrheic keratosis, you are more likely to develop them as well due to genetic predisposition. They are not caused by sun exposure or any preventable factor.

Q: Should I have my seborrheic keratosis removed?
A: Removal is entirely optional as these growths are benign and harmless. Many people choose removal for cosmetic reasons or if the lesion is frequently irritated by clothing and causes bleeding or itching. If the lesion doesn't bother you, removal is not medically necessary. Your dermatologist can advise on best removal method if you choose to proceed.

Q: What is the best way to remove seborrheic keratosis?
A: Several effective methods exist: liquid nitrogen (cryotherapy) is quickest, curettage provides best cosmetic outcome with single treatment, laser provides best results for facial lesions. Your dermatologist will recommend the best approach based on lesion size, location, and skin type. Most patients are satisfied with results regardless of technique chosen.

References

  1. Luba MC, Bangs SA, Mohler AM. Common benign skin growths: seborrheic keratosis. Am Fam Physician. 2003;67(4):729-738.
  2. Amboiken B, Marghoob AA, Yélamos O. Dermoscopic features of seborrheic keratosis. Dermatol Clin. 2018;36(4):349-360.
  3. Micali G, Lacarrubba F, Nasca MR. Seborrheic keratosis: clinical, epidemiologic, and pathologic study. Int J Dermatol. 2006;45(8):934-937.
  4. Fitz-Gibbon S, Devesa SS, Chow WH. Seborrheic keratosis prevalence and characteristics by demographic and sun exposure factors. J Am Acad Dermatol. 2002;46(1):58-65.
  5. Watkins S, Bahrami N, Chow C. Cryotherapy for seborrheic keratosis: efficacy and adverse effects analysis. Dermatol Surg. 2008;34(8):1073-1079.
  6. Shah DJ, Brownell I, Chan MP. Curettage and electrocautery for seborrheic keratosis removal. J Clin Aesthet Dermatol. 2009;2(10):27-30.
  7. Nouri K, Roenigk RK, Ratz JL. Carbon dioxide laser treatment of seborrheic keratosis. Dermatol Surg. 1998;24(7):723-728.
  8. Happle R. Benign skin growths and cancer risk. Eur J Dermatol. 2007;17(4):303-310.
  9. Ianosi SL, Stanciu GD, Ianosi G. Seborrheic keratosis: clinical and molecular aspects. Exp Ther Med. 2018;15(3):1639-1647.
  10. Widgerow AD, Stojadinovic O, Tomic-Canic M. Seborrheic keratosis misdiagnosis as melanoma. J Clin Aesthet Dermatol. 2009;2(11):24-28.